Suche in nationalen und internationalen Patentsammlungen
Einige Inhalte dieser Anwendung sind momentan nicht verfügbar.
Wenn diese Situation weiterhin besteht, kontaktieren Sie uns bitte unterFeedback&Kontakt
1. (PH1/2016/502445) ANTIBODIES DIRECTED AGAINST CD127

Amt : Philippinen
Anmeldenummer: 1/2016/502445 Anmeldedatum: 10.06.2015
Veröffentlichungsnummer: 1/2016/502445 Veröffentlichungsdatum: 06.03.2017
Veröffentlichungsart : A
PCT-Aktenzeichen: Anmeldenummer: PCTEP2015062993 ; Veröffentlichungsnummer: Anklicken zur Anzeige der Daten
IPC:
A61K 39/00
C07K 16/28
A Täglicher Lebensbedarf
61
Medizin oder Tiermedizin; Hygiene
K
Präparate für medizinische, zahnärztliche oder kosmetische Zwecke
39
Medizinische Präparate die Antigene oder Antikörper enthalten
C Chemie; Hüttenwesen
07
Organische Chemie
K
Peptide
16
Immunglobuline, z.B. monoclonale oder polyclonale Antikörper
18
gegen Stoffe aus Tieren oder Menschen
28
gegen Rezeptoren, Zelloberflächen-Antigene oder Zelloberflächen-Determinanten
Anmelder: OSE IMMUNOTHERAPEUTICS
Erfinder: VANHOVE, Bernard
POIRIER, Nicolas
MARY, Caroline
Vertreter: CRUZ MARCELO & TENEFRANCIA
Prioritätsdaten: 15305078.6 23.01.2015 EP
62/010,117 10.06.2014 US
Titel: (EN) ANTIBODIES DIRECTED AGAINST CD127
Zusammenfassung:
(EN) The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127. According to another aspect of the invention antibodies are provided which recognize a human CD127 epitope comprising sequences from the 2b site of CD127, in particular the epitope comprising comprises the human CD127 sequences of domain D1 and of the 2b site of CD127, in particular the epitope comprises at least one sequence from D1 comprising SEQ ID No: 115 (in particular comprising SEQ ID No: 10) and/or SEQ ID No: 111 and / or a sequence from the 2b site comprising the sequence of SEQ ID No: 116 and optionally also comprises SEQ ID No: 117 (in particular comprises SEQ ID No: 111).The antibodies of the invention are suitable for use inorder to remedy to a condition diagnosed in a human patient which results from pathogenesis related to lymphopoiesis, when IL-7 signalling pathways provide contribution to said pathogenesis, especially when an increase in the maturation, more precisely the upregulation of costimulatory molecules, of dendritic cells is undesirable.
Auch veröffentlicht als:
UAa201613258SG11201610036PCA2950823AU2015273532EP3155014KR1020170019417
US20170129959IL249449CN106715471VN52585MYPI 2016002094JP2017522903
TH171839IN201617042413BR112016028755TN2016000528EA201692460RU2016151265
CR20160576WO/2015/189302